Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$123.46 USD

123.46
1,033,841

-3.67 (-2.89%)

Updated May 24, 2024 04:00 PM ET

After-Market: $123.49 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

by Zacks Equity Research

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

by Zacks Equity Research

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Consider for Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

by Zacks Equity Research

Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

by Zacks Equity Research

Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.

Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

by Zacks Equity Research

Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.

Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains

by Zacks Equity Research

Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.

Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

by Zacks Equity Research

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal

by Zacks Equity Research

Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.

Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.

STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.

IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

by Zacks Equity Research

Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

by Zacks Equity Research

Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.

Edgewise (EWTX) Rallies 35% on Issue of New Common Stock

by Zacks Equity Research

Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.

What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 29.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.